Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2023

Li Ziming, Song Zhengbo, Zhao Yanqiu, Wang Pingli, Jiang Liyan, Gong Yi, Zhou Jianying, Jian Hong, Dong Xiaorong, Zhuang Wu, Cang Shundong, Yang Nong, Fang Jian, Shi Jianhua, Lu Junguo, Ma Rui, Wu Ping, Zhang Yingqian, Song Mengmeng, Xu Chun-Wei, Shi Zhe, Zhang Ling, Wang Yaolin, Wang Xicheng, Zhang Yiping, Lu Shun

Abstract excerpt

INTRODUCTION: D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D-1553 in patients with KRAS G12C-mutated NSCLC in multiple sites in the People's Republic of China. METHODS: Patients with KRAS G12C-mutated NSCLC have administrated D-1553 600 mg orally once daily, 800 mg once daily, 1200 mg once daily, 400 mg twice a...

Topics

Join the communities discussing this publication.

Brain Neoplasms
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 36948246
DOI: 10.1016/j.jtho.2023.03.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results.PMID 36948246Read ↗

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.Semantic proximity Read ↗

D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity.Semantic proximity Read ↗

143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models.Semantic proximity Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.Semantic proximity Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human StudySemantic proximity Read ↗

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Semantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.Semantic proximity Read ↗

Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.